Patent 7888361 was granted and assigned to Curis (company) on February, 2011 by the United States Patent and Trademark Office.
The present invention relates to tyrosine kinase inhibitors that contain a zinc-binding moiety and their use in the treatment of tyrosine related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.